Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors

Genmab

Status and phase: Withdrawn; Phase 2

Conditions: Non-small Cell Lung Cancer

Treatments: Drug: zalutumumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT01449357

GEN210

Details and patient eligibility

About

A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have documented disease progression after TKI treatment (verified by CT scan and/or MRI according to RECIST).

Exclusion criteria

• Estimated life expectancy of less than 3 months.

• Received the following treatments within 2 weeks prior to Visit 2:

  • Cytotoxic or cytostatic anti-cancer chemotherapy
  • Total resection or irradiation of the target lesion
  • Any investigational agent

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

zalutumumab

Experimental group

Treatment:

Drug: zalutumumab